A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Advanced Accelerator Applications
Dana-Farber Cancer Institute
SCRI Development Innovations, LLC
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Ipsen
Novartis
Amgen
University of Iowa
Eli Lilly and Company
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Mateon Therapeutics
Columbia University
Vanderbilt-Ingram Cancer Center
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Novartis